Get started
PFIZERPFIZERPFIZER

PFIZER

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

PFE trade ideas

Pfizer here we go! Holding while price is green. 🚀🚀🚀Stocks trend. A lot. Much more than Forex. Pfizer is going parabolic while breaking all time high and $50, this could be the start of a big trend, or it might not. Let's look at a few examples starting with Pfizer. Clearly we see how with stocks we can make big multiples of our risk. Like 25R in stocks versus 10R in Forex (for example, reality is probably close to that) Zooming in the little impulses: I don't know how many "casuals" are interested in Pfizer, but it is a word billions of people know. We can look at Tesla & PonziStop: How about another one just to illustrate? So the question is, how to hold on but without giving back all profits? 1 solution is sell half once a stop is reached keep half with a much wider stop. Smooths out the PnL. And this is probably what I'll do. On a longer TF I'd look to add, here this is all a short term play, expecting the stock to go parabolic. I am at exactly 5 times my risk (counting spreads) as of writting this. Hasn't even been 2 weeks yet. Talk about a monster. This risk a monster correction too. Hopefully it warns before.
NYSE:PFELong
by MrRenev
4
PFE Uptrend Strong Waiting for pullback to 50 MAPfizer is in a strong uptrend and its hourly keeps coming back to the 50 MA. Each time it has come back to the 50 MA, it has met at a support area. I believe we may see PFE run a bit higher before it returns to the 50 MA as the RSI is undecided (although slightly on a decline). The hourly wicks also do not show any signs of a pullback yet, which supports this idea of a new ATH in the making. I am holding my PFE call until I see some more resistance, but once the tide changes for short term bears I will sell and wait until PFE pulls back to 48.50 (and closes green after touching the 50 MA) before entering calls.
NYSE:PFE
by MathewPiedoux
1
The Story of Pfizer: The Big Swing - A 22% WinnerOffshore equities is the name of the game. Let me say that again: OFFSHORE EQUITIES IS THE NAME OF THE GAME. Despite the US being expensive from a valuation perspective, there are always an TRADING opportunities for clients to make money. From small to mid, to large to mega-cap. Across sectors and industries as well as thematic opportunities, where momentum can run for days and weeks on end. For the week starting 05 July, we included Pfizer in our report, with the following comment: "What’s Happening In Healthcare? Pfizer (PFE, 39.73) - In April we discussed the healthcare sector, where we noted some attractive medium term setups. Have a look at a PFE where we note a low volume consolidation while the price trades below a 32-month downward trend. Figures in USD." Over the next for weeks the stock broke to the upside to take a momentum run not seen in a while. As at this week's peak, the name was higher by 22% over the 5-week period. Well done to all who managed to catch this!!! What's next? Where is the next big swing? Which sector? Which theme? Is your broker helping you find these opportunities, or is he leaving you scratching your head while he collects his monthly fees? As a researcher/analyst, it's my goal to find opportunities that make a difference to client accounts, helping them benefit from market moves and guiding them via my lens and perspective of markets. If you would like to gain real-time access to these opportunities, get in touch with me today.
NYSE:PFE
by LD_Perspectives
PFIZER INC.:FUNDAMENTAL ANALYSIS+PRICE ACTION|NEXT TARGET|LONG🔔Earlier this month, Pfizer announced promising first-line results from a Phase 2b/3 trial testing the JAK inhibitor ritecitinib for the treatment of alopecia(baldness), suggesting that the drug could finally be approved to treat this autoimmune disease that causes hair loss. But as Jeff Little noted, "The FDA has recently been paying increased attention to the potential side effects of JAK inhibitors, which belong to a family of drugs called DMARDs (disease-modifying anti-rheumatic drugs)." Let's look at the results of the study, what the FDA's concerns mean for this drug and others like it, and whether pharmaceutical giant Pfizer has a chance to make a name for itself in the growing global market for alopecia medications. Pfizer's phase 2b/3 study of the drug ritlecitinib examined the drug's effect on alopecia treatment in a randomized clinical trial involving 719 patients. These patients were 12 years of age or older, had 50% or more scalp hair loss (as measured by the Severity of Alopecia Tool scale, or SALT), and had experienced a current episode lasting six months to 10 years. Pfizer remarked that a clinically meaningful proportion of patients who received 30 mg or 50 mg of ritlecitinib daily achieved less than 20% head hair loss on the SALT scale after 24 weeks of treatment opposed to placebo, consistent with the study's primary efficacy endpoint of improved head hair regrowth. According to Pfizer, the scientific basis for ritlecitinib is that the drug stops the body's immune system from attacking hair follicles, which is thought to contribute to hair loss in patients with alopecia. Despite the study's encouraging results, it's worth noting that ritlecitinib's path to FDA approval for the alopecia indication (or for vitiligo, rheumatoid arthritis, Crohn's disease, and ulcerative colitis, for that matter) will be even more thorough than usual because of its special class of drugs. Ritlecitinib belongs to the class of Janus kinase inhibitors, or JAK inhibitors, which have been under scrutiny by the FDA lately. As per Fierce Pharma, a post-marketing study of Pfizer's JAK-inhibitor Xeljanz revealed serious heart and cancer side effects when the study results were published at the beginning of the year. This urged the FDA to delay the potential approval of the JAK inhibitor back in February while the agency investigates further. Xeljanz was first approved by the FDA in 2012 to treat rheumatoid arthritis, or RA, an autoimmune disease that can cause joint pain and damage throughout the body. The drug was also approved by the FDA in 2017 to treat psoriatic arthritis and in 2018 to treat ulcerative colitis. Although no serious adverse cardiac events or deaths were reported in Pfizer's study of ritlecitinib, it is in this class of drugs. As a result, its future remains very uncertain. If the JAK inhibitor class ultimately withstands increased regulatory scrutiny and the efficacy of ritlecitinib safely treating alopecia persists, the drug could provide a reliable revenue stream for Pfizer. To support this thesis, let's take a look at the global alopecia market and its growth forecast. Pointing to the "increasing prevalence of hair loss" as well as "technological advances in alopecia treatment," Grand View Research believes that the total global alopecia market will grow at an annual rate of 8.1% from $7.6 billion in 2020 to $14.2 billion by 2028. If the alopecia market stays at 35.2% of the total global alopecia market as it was in 2020, Pfizer's total addressable market in this area will be $5 billion by 2028. Given that Pfizer will likely face competition from Concert Pharmaceuticals' JAK inhibitor CTP-543 (first Phase 3 results not expected until 2022) and Eli Lilly and Incyte's JAK inhibitor baricitinib (currently awaiting FDA decision) when it enters the alopecia market, a fragmented market share of 15% is realistic. This would result in $750 million in annual revenue associated with the alopecia drug indications by 2028, which is about 1% of Pfizer's projected 2021 revenue of $78-80 billion. As questions arise about whether JAK inhibitors such as ritlecitinib will be able to gain regulatory approval in the future, it is worth noting that Pfizer does not significantly necessitate that approval to boost earnings in the coming years. In addition to the BNT162b2 COVID-19 vaccine, developed with German company BioNTech, Pfizer also expects to be able to apply for approval in the fourth quarter of this year for the emergency use of the oral antiviral drug COVID-19, known as PF-07321332. Keith Speights thinks this could be a real blockbuster given the huge addressable market, especially since Pfizer won't have to share the profits from oral therapy as it does with BioNTech in the case of BNT162b2. In addition to COVID-19, Pfizer's oncology biosimilars (Ruxience, Zirabev, and Retacrit) tripled their combined sales from $107 million in the second quarter of 2020 to $352 million in the second quarter of 2021, another good catalyst for growth going forward. Nearly half of Pfizer's projected sales this year will come from the $33.5 billion the company expects from its BNT162b2 COVID-19 vaccine (after splitting revenue with a partner, BioNTech). This is based on the 2.1 billion doses the company estimates will be delivered this year. Given sales of the breast cancer drug Ibrance ($1.4 billion through Q2 2021) and the anticoagulant Eliquis ($1.5 billion through Q2 2021), we can assume that these two drugs will also bring in about $3 billion each.
NYSE:PFELong
by FOREXN1
6
Ok. Pfizer is going NUTS! 🚀🚀🚀Nothing is more profitable than fear. I think Pfizer profits have doubled by Q2 and it's getting even crazier, way crazier. The whole west is throwing money at them with government and most urbanites in total fear. They don't even care how much it costs. Destroy a country? Lose 10% of GDP? They don't care, just name your price. Take AMZN for example. Went vertical, retested ATH, then to the moon. In the short term (2-3 months or even less) it can be really profitable. Who cares if Pfizer gets destroyed by crowds after we made our money? It won't happen overnight (probably). Here it's different from Amazon there is no reason for the company to trend for years (for now). It's really short term with the hysterical fear pushing profits to incredible levels. Share prices have a tendency to retrace after breaking ATH, once again, profitable in the short term. I'm not stock trader but here it is really juicy. I'm sure there are similar examples? Price just going vertical... 1999 bubble for sure... I am not experienced enough but I assume it always or almost always retests ATH I'm sure it's possible Pfizer just goes vertical, the noob bagholding investors as always will want to greedily snatch their profits the moment they see some green and cause a pullback but euphoria could absorb the selling. Something like that.... Consolidation... And again... Got to check my favorite example Moderna for 2 years has simply been in a beautiful trend, a work of art. And it is up more than 1000% since 2020. Some to compare moderna to: Other cool trends
NYSE:PFELong
by MrRenev
4
PFE (PFIZER) At A crucial Breakout LevelTraders, PFE (PFIZER) has risen to the a crucial level. Watch out for the move down. However a breakout above from this level can take this to 49/50 price and even higher. Rules: 1. Never trade too much 2. Never trade without a confirmation 3. Never rely on signals, do your own analysis and research too ✅ If you found this idea useful, hit the like button, subscribe and share it in other trading forums. ✅ Follow me for future ideas, trade set ups and the updates of this analysis ✅ Don't hesitate to share your ideas, comments, opinions and questions. Take care and trade well -Vik ____________________________________________________ 📌 DISCLAIMER The content on this analysis is subject to change at any time without notice, and is provided for the sole purpose of education only. Not a financial advice or signal. Please make your own independent investment decisions. ____________________________________________________
NYSE:PFE
by vikinsa
3